FMS样酪氨酸激酶3(Flt3)多克隆抗体(生物素标记)
Biotin-Linked Polyclonal Antibody to FMS Like Tyrosine Kinase 3 (Flt3)
CD135; STK1; FLK2; Fms-Related Tyrosine Kinase 3; Stem Cell Tyrosine Kinase 1; FL Cytokine Receptor; Fetal Liver Kinase-2
- 编号LAA039Mu71
- 物种Mus musculus (Mouse,小鼠) 相同的名称,不同的物种。
- 来源抗体标记
- Ig类型 IgG
- 纯化方式抗原特异性亲和纯化
- 标记物生物素
- 原抗体 PAA039Mu01-FMS样酪氨酸激酶3(Flt3)多克隆抗体
- 缓冲液成份0.01M 磷酸盐缓冲液(pH7.4,containing 0.05% Proclin-300,50% glycerol)
- 性状液体
- 浓度500µg/mL
- 且适物种-
- 应用WB; IHC; ICC.
如果抗体需用于流式细胞术,请参见流式抗体。 - 下载 英文说明书 中文说明书
- 规格 20µl100µl 200µl 1ml 10ml
- 价格 ¥ 641 ¥ 1495 ¥ 2136 ¥ 5340 ¥ 21360
- 欲了解实际交易价格和更多情况,请与当地经销商联系!
特异性
该抗体是针对Flt3的兔多克隆抗体。在免疫组织化学染色和免疫印迹实验中能识别Flt3。
用法
[ APPLICATIONS ]
Western blotting: 0.5-2ug/ml
Immunocytochemistry in formalin fixed cells: 5-20ug/ml
Immunohistochemistry in formalin fixed frozen section: 5-20ug/ml
Immunohistochemistry in paraffin section: 5-20ug/ml
Enzyme-linked Immunosorbent Assay: 0.05-2ug/ml
Optimal working dilutions must be determined by end user.
储存
经常使用则4°C保存。-20°C保存不超过两年。避免反复冻融。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。
赠品
增值服务
相关产品
编号 | 适用物种:Mus musculus (Mouse,小鼠) | 应用(仅供研究使用,不用于临床诊断!) |
RPA039Mu01 | FMS样酪氨酸激酶3(Flt3)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA039Mu01 | FMS样酪氨酸激酶3(Flt3)多克隆抗体 | WB; IHC; ICC; IP. |
LAA039Mu71 | FMS样酪氨酸激酶3(Flt3)多克隆抗体(生物素标记) | WB; IHC; ICC. |
参考文献
杂志 | 参考文献 |
Frontiers in physiology | Alpha-1 Antitrypsin Prevents the Development of Preeclampsia Through Suppression of Oxidative Stress [pubmed:27303303] |
PLoS One | Evaluation of surfactant proteins A, B, C, and D in articular cartilage, synovial membrane and synovial fluid of healthy as well as patients with osteoarthritis and … [Pubmed: 30235245] |
Bioscience Reports | N-Acetylcysteine inhalation improves pulmonary function in patients received Liver Transplantation. [Doi: 10.1042/BSR20180858] |
Molecular Neurobiology | Elevated levels of multifunctional surfactant proteins in cerebrospinal fluid are associated with signs of increased cerebrospinal fluid flow in cranial magnetic … [Doi: 10.1007/s12035-017-0835-5] |
Cancers | Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia [Pubmed: 31718075] |
留言咨询